Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRIS: Neoadjuvant Chemoradiotherapy and Tislelizumab for Esophageal Squamous Cell Carcinoma
NCT06303583Phase 2Enrolling by invitation
- Start
- Jun 2022
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoints: Pathological Complete Response Rate at 1 year and Incidence of Adverse Events and Serious Adverse Events. Started Jun 2022; status: enrolling by invitation.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06303583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06303583.